Host MMP-mediated regulation of the vicious cycle of prostate to bone metastases

宿主MMP介导的前列腺骨转移恶性循环的调节

• 批准号: 8657863
• 负责人: Conor C Lynch
• 金额: $ 29.2万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8657863
• 关键词: Adverse effects; Affect; American Cancer Society; Animal Model; Animal Testing; Animals; Area; Behavior; Binding Proteins; Biological Availability; Biology; Bone Growth; Bone neoplasms; Bone remodeling; Cancer Etiology; Cell Communication; Cells; Cessation of life; Clinical; Communication; Data; Development; Differentiation and Growth; Enzymes; Event; Extracellular Matrix; Figs - dietary; Gelatinase A; Gelatinase B; Genes; Growth Factor; Human; Individual; Knockout Mice; Lesion; Ligands; Light; Malignant neoplasm of prostate; Matrilysin; Matrix Metalloproteinase Inhibitor; Matrix Metalloproteinases; Mediating; Metastatic Neoplasm to the Bone; Modeling; Morbidity - disease rate; Neoplasm Metastasis; Nuclear; Osteoblasts; Osteoclasts; Osteogenesis; Osteolysis; Osteolytic; Parathyroid Hormone Receptor; Parathyroid gland; Pathological fracture; Patients; Peptide Receptor; Peptides; Procedures; Process; Prostate; Prostatic Neoplasms; Quality of life; Regulation; Resolution; Rodent Model; Role; Site; Stromelysin 1; Surface; Technology; Testing; Therapeutic; Time; Transforming Growth Factor beta; Transforming Growth Factors; Work; base; bone; bone cell; collagenase 3; cytokine; experience; human disease; innovation; insight; intense pain; knockout animal; men; neoplastic cell; new therapeutic target; novel; novel therapeutics; osteoclastogenesis; receptor; response; single photon emission computed tomography; tumor growth

Significance: In 2008 the American Cancer Society predicted that 28,660 men will die from prostate cancer making it the second leading cause of cancer death in men. Bone is an extremely common site for prostate cancer metastasis. Prostate to bone metastases promote bone growth and destruction by manipulating normal host cells of the bone known as osteoblasts osteoclasts respectively. As a result, the patient often experiences intense pain, spontaneous fractures and morbidity that dramatically affect his quality of life. Prostate to bone metastases are incurable and the current treatment options are limited. In order to identify new therapeutic targets, a comprehensive understanding of how the prostate tumor cells communicate with the normal bone cells to induce bone growth and destruction is required. Rationale: We have generated a unique animal model of prostate tumor induced bone growth and destruction that accurately mimics the human disease. We have used the model to analyze the expression of thousands of genes in prostate bone tumors and have found that several enzymes known as matrix metalloproteinases (MMPs) are present at high levels (MMP-2, MMP-3, MMP-7, MMP-9 and MMP-13) and that they are predominantly expressed by the normal bone cells. MMPs are considered matrix 'bulldozers' but the PI using emerging data proposes a new concept that MMPs can facilitate cell-cell communication by altering the activity and availability of key substrates responsible for prostate cancer induced bone formation and destruction, namely parathyroid related peptide (PTHrP), receptor activator of nuclear kappa B ligand (RANKL) and transforming growth factor beta (TGF¿). Based on these observations, we hypothesize that individual host derived MMPs are key contributors to prostate tumor induced bone destruction and bone formation by virtue of their ability to regulate the activity of factors that control prostate cancer-bone communication. Approaches: In Specific Aim 1, we will use MMP 'knockout' animals test the contribution of these individual bone derived MMPs to prostate tumor induced bone destruction and formation using animal models that mimic the human disease. In Specific Aim 2, we will determine how MMPs can impact prostate tumor induced changes in the bone by controlling the bioactivity and bioavailability of PTHrP and RANKL and TGF¿. Innovation and Impact: The proposed study has several innovations; 1) It will be the first to explore the contribution of individual host derived MMPs to prostate tumor induced bone formation/destruction using animal models that mimic the human disease; 2) It will be the first to explore the impact of host MMPs on the bioactivity of PTHrP, RANKL and TGF¿ in the prostate tumor-bone microenvironment. The results of our proposed studies will enhance our understanding of basic tumor-bone biology, change the concept of the field as to how MMPs work and will reveal potentially new therapeutic targets that can be used to treat men with prostate to bone metastses.

2008年，美国癌症协会预测，28,660名男性将死于前列腺癌。 使其成为男性癌症死亡的第二大原因。骨是前列腺增生的一个非常常见的部位。 癌症转移前列腺骨转移促进骨生长和破坏通过操纵正常 骨的宿主细胞分别称为成骨细胞破骨细胞。因此，患者经常会经历 剧烈的疼痛，自发性骨折和发病率，严重影响了他的生活质量。前列腺至骨 转移是不可治愈的，目前的治疗选择是有限的。为了发现新的治疗方法 目标，全面了解前列腺肿瘤细胞如何与正常骨沟通 细胞诱导骨生长和破坏是必需的。 原理：我们已经建立了一个独特的前列腺肿瘤诱导骨生长和破坏的动物模型 精确模拟人类疾病的病毒我们已经使用该模型分析了数千个 前列腺骨肿瘤中的基因，并发现几种称为基质金属蛋白酶的酶， 在一些实施方案中，基质金属蛋白酶（MMP）以高水平存在（MMP-2、MMP-3、MMP-7、MMP-9和MMP-13），并且它们是 主要由正常骨细胞表达。MMP被认为是矩阵“推土机”，但PI使用 新兴的数据提出了一个新的概念，即MMPs可以通过改变活性来促进细胞间的通讯， 以及负责前列腺癌诱导的骨形成和破坏的关键底物的可用性， 即甲状旁腺相关肽（PTHrP）、核κ B配体受体激活剂（RANKL）和 转化生长因子β（TGF β）。基于这些观察，我们假设个体宿主 衍生的MMP是前列腺肿瘤诱导的骨破坏和骨形成的关键因素， 它们调节控制前列腺癌-骨通讯的因子的活性的能力。 方法：在具体目标1中，我们将使用MMP '敲除'动物测试这些个体的贡献 骨源性MMPs对前列腺肿瘤诱导的骨破坏和骨形成的作用 人类疾病。在具体目标2中，我们将确定MMPs如何影响前列腺肿瘤诱导的 通过控制PTHrP、RANKL和TGF？的生物活性和生物利用度， 创新和影响：拟议的研究有几个创新; 1）它将是第一个探索 使用免疫组织化学方法检测单个宿主来源的MMP对前列腺肿瘤诱导的骨形成/破坏的贡献 模拟人类疾病的动物模型; 2）这将是第一个探索宿主MMPs对 PTHrP、RANKL和TGF β在前列腺肿瘤-骨微环境中的生物活性。的成果 提出的研究将提高我们对基本肿瘤-骨生物学的理解，改变该领域的概念， MMPs是如何工作的，并将揭示潜在的新的治疗靶点，可用于治疗男性 前列腺到骨癌

项目成果

Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

• DOI: 10.1158/1535-7163.mct-16-0315-t
• 发表时间: 2017-03
• 期刊: Molecular cancer therapeutics
• 影响因子: 5.7
• 作者: Tauro M;Shay G;Sansil SS;Laghezza A;Tortorella P;Neuger AM;Soliman H;Lynch CC
• 通讯作者: Lynch CC

Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling.

• DOI: 10.1007/s10585-014-9674-1
• 发表时间: 2014-12
• 期刊: Clinical & experimental metastasis
• 影响因子: 4
• 作者: Gallaher J;Cook LM;Gupta S;Araujo A;Dhillon J;Park JY;Scott JG;Pow-Sang J;Basanta D;Lynch CC
• 通讯作者: Lynch CC

Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.

• DOI: 10.1038/srep29384
• 发表时间: 2016-07-14
• 期刊: Scientific reports
• 影响因子: 4.6
• 作者: Cook LM;Araujo A;Pow-Sang JM;Budzevich MM;Basanta D;Lynch CC
• 通讯作者: Lynch CC

Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.

• DOI: 10.1007/s10555-014-9494-4
• 发表时间: 2014-09
• 期刊: CANCER AND METASTASIS REVIEWS
• 影响因子: 9.2
• 作者: Cook, Leah M.;Shay, Gemma;Aruajo, Arturo;Lynch, Conor C.
• 通讯作者: Lynch, Conor C.

An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.

• DOI: 10.1158/0008-5472.can-13-2652
• 发表时间: 2014-05-01
• 期刊: Cancer research
• 影响因子: 11.2
• 作者: Araujo A;Cook LM;Lynch CC;Basanta D
• 通讯作者: Basanta D